Eye drops could replace needle injections for wet AMD
Disease control
Not yet recruiting
This Phase 2a trial tests SCAI-005 eye drops in 50 adults with wet age-related macular degeneration (AMD). Participants will receive either a low dose, high dose, or placebo drops three times daily. The study aims to see if the drops can reduce retinal swelling and control the di…
Phase: PHASE2 • Sponsor: SCAI Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC